Development of an inhaled anti-TSLP therapy for asthma
Pulmonary Pharmacology & Therapeutics · 2023-02 · 78 · 102184
DOI: 10.1016/j.pupt.2022.102184 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pulmonary Pharmacology & Therapeutics, 2023-02. Verfasst von Paul M O'Byrne und 5 weiteren Autor:innen. Beteiligte Einrichtung: Firestone Institute for Respiratory Health, St. Joseph's Healthcare and McMaster University, Hamilton, Ontario, Canada. Electronic address: obyrnep@m…. Hauptthemen laut MEDLINE: Asthma, Thymic Stromal Lymphopoietin. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 143 Literaturangaben. Gefördert von: Novartis.
Abstract (Originalsprache)
Thymic stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine, acts as a key mediator in airway inflammation and modulates the function of multiple cell types, including dendritic cells and group 2 innate lymphoid cells. TSLP plays a role in asthma pathogenesis as an upstream cytokine, and data suggest that TSLP blockade with the anti-TSLP monoclonal antibody, tezepelumab, could be efficacious in a broad asthma population. Currently approved asthma biologic therapies target allergic or eosinophilic disease and require phenotyping; therefore, an unmet need exists for a therapy that can address Type 2 (T2)-high and T2-low inflammation in asthma. All currently approved biologic treatments are delivered intravenously or subcutaneously; an inhaled therapy route that allows direct targeting of the lung with reduced systemic impact may offer advantages. Currently in development, ecleralimab (CSJ117) represents the first inhaled anti-TSLP antibody fragment that binds soluble TSLP and prevents TSLP receptor activation, thereby inhibiting further inflammatory signalling cascades. This anti-TSLP antibody fragment is being developed for patients with severe uncontrolled asthma despite standard of care inhaled therapy. A Phase IIa proof of concept study, using allergen bronchoprovocation as a model for asthma exacerbations, found that ecleralimab was well-tolerated and reduced allergen-induced bronchoconstriction in adult patients with mild asthma. These results suggest ecleralimab may be a promising, new therapeutic class for asthma treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Firestone Institute for Respiratory Health, St. Joseph's Healthcare and McMaster University, Hamilton, Ontario, Canada. Electronic address: obyrnep@mcmaster.ca.
- Rutgers University, New Jersey, USA.
- Department of Pulmonary Medicine, University Hospital Essen, Germany.
- Novartis Pharma AG, Basel, Switzerland.
- Novartis Institutes for Biomedical Research, Massachusetts, USA.
- Novartis Pharmaceuticals Corporation, New Jersey, USA. Electronic address: pablo.altman@novartis.com.
Förderung
- Novartis
Zitieren
APA
O'Byrne, P. M., Panettieri, R. A., Taube, C., Brindicci, C., Fleming, M., & Altman, P. (2023). Development of an inhaled anti-TSLP therapy for asthma. Pulmonary Pharmacology & Therapeutics, 78, 102184. https://doi.org/10.1016/j.pupt.2022.102184
Vancouver
O'Byrne PM, Panettieri RA, Taube C, Brindicci C, Fleming M, Altman P. Development of an inhaled anti-TSLP therapy for asthma. Pulmonary Pharmacology & Therapeutics. 2023;78:102184. doi:10.1016/j.pupt.2022.102184
BibTeX
@article{OByrne2023,
author = {O'Byrne, Paul M and Panettieri, Reynold A and Taube, Christian and Brindicci, Caterina and Fleming, Margaret and Altman, Pablo},
title = {Development of an inhaled anti-TSLP therapy for asthma},
journal = {Pulmonary Pharmacology & Therapeutics},
year = {2023},
volume = {78},
pages = {102184},
doi = {10.1016/j.pupt.2022.102184}
}
EUVIMED